Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Industry News

TriNetX's Real-World Data and Analytics Platform Used to Compare Antihypertensive Treatments and Cardiovascular Events; Findings Published in the Journal of Clinical Hypertension

April 18, 2019

News Industry News

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

April 09, 2018

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

News Industry News

Medtronic Announces New SPYRAL HTN Global Clinical Trial Program for Renal Denervation

April 01, 2015

News Industry News

Randomized Sham-Controlled Trial Examines Blood Pressure Effects of Renal Denervation in Patients with Mild Refractory Hypertension

September 16, 2014

News Industry News

Twelve-Month Data from St. Jude Medical EnligHTN Renal Denervation System Show Continued Safety and Efficacy for Patients

September 13, 2014

News Industry News

Preliminary Results From the St. Jude Medical EnligHTN III Study Demonstrate Renal Denervation Is Safe and Effective

May 22, 2014

News Industry News

Medtronic Randomizes First Patients in SYMPLICITY HTN-4, the First U.S. Renal Denervation Clinical Study for Patients with Moderate Uncontrolled Hypertension

December 16, 2013

News Industry News

New Data Continue To Show Significant and Sustained Blood Pressure Reduction

October 29, 2013

News Industry News

NEW DATA CONTINUE TO SHOW SIGNIFICANT AND SUSTAINED BLOOD PRESSURE REDUCTION WITH BOSTON SCIENTIFIC VESSIX™ RENAL DENERVATION SYSTEM

October 28, 2013

News Industry News

Medtronic Presents Final Three-Year Data From Symplicity HTN-1 Showing Significant and Sustained Drops in Blood Pressure After Treatment with the Symplicity(TM) Renal Denervation System

September 03, 2013

News Industry News

St. Jude Medical Initiates First US Clinical Study of the EnligHTN Renal Denervation System for Drug-Resistant High Blood Pressure

June 04, 2013

News Industry News

One Year Data from St. Jude Medical Study Demonstrates Safe, Rapid and Sustained Blood Pressure Reduction with EnligHTN Renal Denervation Technology

May 23, 2013

News Industry News

New Data Demonstrate Significant And Sustained Blood Pressure Reduction With Boston Scientific Vessix™ Renal Denervation System

May 22, 2013

News Industry News

New Data Reinforce Significant Blood Pressure Reduction Sustained to Two Years Using the Symplicity™ Renal Denervation System

March 09, 2013

News Industry News

Significant Blood Pressure Reduction from St. Jude Medical's EnligHTN Renal Denervation Technology is Safe, Effective and Sustained at Six Months

November 04, 2012

News Industry News

Two-Year Follow-Up Of Symplicity Htn-1 Data Confirms Significant And Sustained Blood Pressure Reduction In Expanded Cohort Of Patients

October 22, 2012

News Industry News

Renal Denervation Technology from St. Jude Medical Demonstrates Significant Reduction in Blood Pressure

May 16, 2012

News Industry News

Medtronic Starts Landmark Study of Hypertension Treatment

October 26, 2011

News Industry News

Medtronic Gets Go-Ahead from FDA for Study of Novel Treatment for High Blood Pressure

July 11, 2011

Advertisement

TriNetX's Real-World Data and Analytics Platform Used to Compare Antihypertensive Treatments and Cardiovascular Events; Findings Published in the Journal of Clinical Hypertension

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Medtronic Announces New SPYRAL HTN Global Clinical Trial Program for Renal Denervation

Randomized Sham-Controlled Trial Examines Blood Pressure Effects of Renal Denervation in Patients with Mild Refractory Hypertension

Twelve-Month Data from St. Jude Medical EnligHTN Renal Denervation System Show Continued Safety and Efficacy for Patients

Preliminary Results From the St. Jude Medical EnligHTN III Study Demonstrate Renal Denervation Is Safe and Effective

Medtronic Randomizes First Patients in SYMPLICITY HTN-4, the First U.S. Renal Denervation Clinical Study for Patients with Moderate Uncontrolled Hypertension

New Data Continue To Show Significant and Sustained Blood Pressure Reduction

NEW DATA CONTINUE TO SHOW SIGNIFICANT AND SUSTAINED BLOOD PRESSURE REDUCTION WITH BOSTON SCIENTIFIC VESSIX™ RENAL DENERVATION SYSTEM

Medtronic Presents Final Three-Year Data From Symplicity HTN-1 Showing Significant and Sustained Drops in Blood Pressure After Treatment with the Symplicity(TM) Renal Denervation System

St. Jude Medical Initiates First US Clinical Study of the EnligHTN Renal Denervation System for Drug-Resistant High Blood Pressure

One Year Data from St. Jude Medical Study Demonstrates Safe, Rapid and Sustained Blood Pressure Reduction with EnligHTN Renal Denervation Technology

New Data Demonstrate Significant And Sustained Blood Pressure Reduction With Boston Scientific Vessix™ Renal Denervation System

New Data Reinforce Significant Blood Pressure Reduction Sustained to Two Years Using the Symplicity™ Renal Denervation System

Significant Blood Pressure Reduction from St. Jude Medical's EnligHTN Renal Denervation Technology is Safe, Effective and Sustained at Six Months

Two-Year Follow-Up Of Symplicity Htn-1 Data Confirms Significant And Sustained Blood Pressure Reduction In Expanded Cohort Of Patients

Renal Denervation Technology from St. Jude Medical Demonstrates Significant Reduction in Blood Pressure

Medtronic Starts Landmark Study of Hypertension Treatment

Medtronic Gets Go-Ahead from FDA for Study of Novel Treatment for High Blood Pressure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content